Received: 8 November 2022
Accepted: 21 March 2023
First Online: 15 April 2023
: This study was conducted in accordance with ethical standards, approved by the Advarra Institutional Review Board, Columbia, MD, USA, and listed in clinicaltrials.gov (NCT05192590). Voluntary, informed consent was obtained from all participants.
: Not applicable.
: CPVs®, QURE Healthcare’s proprietary simulated case tool, were used to collect data and score the responses. Three authors (JS, CW, and RH) are employees of Aegis Sciences Corporation, who funded the study. Otherwise, there are no disclosures.